Nurix Therapeutics Inc (NAS:NRIX)
$ 15.9 0.95 (6.35%) Market Cap: 970.97 Mil Enterprise Value: 698.12 Mil PE Ratio: 0 PB Ratio: 4.35 GF Score: 67/100

Nurix Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 11, 2022 / 06:15PM GMT
Release Date Price: $12.37 (-16.53%)
Gil Blum
Needham & Co. - Analyst

Good afternoon, everyone. My name is Gil Blum, and I'm a senior biotech analyst here at Needham and Company, covering immuno-oncology and the gene therapy subsectors. It is my pleasure to have with me today Nurix's management team, including Dr. Arthur Sands and Robert Brown, EVP of Clinical Development. As a reminder, any of you who are watching through our conference portal, are able to submit questions via the Ask a Question box below the video feed window. So just to dive in here, Arthur, can you provide some introductory remarks for Nurix and its protein degradation technology?

Arthur Sands
Nurix Therapeutics Inc. - President & CEO

Sure, Gil, and thanks for having us and to the entire Needham team. We look forward to someday being in person again. Before I provide some introduction, I should mention we will be making certain forward-looking statements, and I refer everyone to our filings with the SEC regarding risk factors. So we are focused on targeted protein modulation, which is inclusive of both targeted

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot